NasdaqGS:ACADBiotechs
ACADIA Pharmaceuticals (ACAD): Evaluating Valuation After New LOTUS Study Evidence for DAYBUE in Rett Syndrome
ACADIA Pharmaceuticals (ACAD) is making headlines after interim results from its LOTUS study were published in a leading medical journal, sparking interest among both investors and the wider healthcare community. The study highlights DAYBUE, currently the only FDA-approved treatment for Rett syndrome in the US and Canada, with caregiver-reported improvements in behavioral symptoms and manageable gastrointestinal side effects. For anyone tracking ACADIA's progress in rare disease innovation,...